https://mindmedicinelaw.com/briefing/fda-holds-landmark-public-hearing-on-psychedelics-policy-2026-20260917-42778The Psychedelic Journalen2026-09-17T22:04:29.957310+00:00FDA Holds Landmark Public Hearing on Psychedelics Policy (2026)fda psychedelics hearing, maps, psychedelic regulation, clinical trial policy, us drug policy, psychedelic research, mdma, psilocybin, federal law, drug approval processhttps://mindmedicinelaw.com/briefing/fda-engages-on-psychedelic-therapy-policy-and-movement-tensions-20260917-42621The Psychedelic Journalen2026-09-17T15:08:41.603058+00:00FDA Engages on Psychedelic Therapy: Policy and Movement Tensionsfda psychedelic therapy, psychedelic regulation, clinical trials, policy guidance, access and equity, movement priorities, drug approval process, mental health innovation, risk managementhttps://mindmedicinelaw.com/briefing/clearmind-medicine-s-fda-testimony-psychedelic-policy-and-meai-trial-insights-20260917-42620The Psychedelic Journalen2026-09-17T15:05:32.330149+00:00Clearmind Medicine's FDA Testimony: Psychedelic Policy and MEAI Trial Insightsfda psychedelic hearing, clearmind medicine, meai clinical trial, patient access, psychedelic policy, novel psychoactive compounds, regulatory engagement, safety and efficacy data, clinical trial designhttps://mindmedicinelaw.com/briefing/psychedelics-and-traumatic-brain-injury-new-qualitative-evidence-from-participan-20260916-42509The Psychedelic Journalen2026-09-17T15:09:04.040040+00:00Psychedelics and Traumatic Brain Injury: New Qualitative Evidence from Participant Narrativespsychedelics, traumatic brain injury, tbi recovery, qualitative research, neurorehabilitation, clinical trials, subjective outcomes, mental health, policy gapshttps://mindmedicinelaw.com/briefing/preparedness-and-risk-in-oregon-psilocybin-consult-patients-20260916-42510The Psychedelic Journalen2026-09-17T15:07:31.219583+00:00Preparedness and Risk in Oregon Psilocybin Consult Patientspsilocybin, oregon, psychedelic consultation, risk reduction, trauma prevalence, clinical preparedness, psychedelic policy, psychiatric care, regulated accesshttps://mindmedicinelaw.com/briefing/psilocybin-clinical-trial-reduces-depression-alters-self-concept-20260916-42547The Psychedelic Journalen2026-09-17T15:06:48.075944+00:00Psilocybin Clinical Trial Reduces Depression, Alters Self-Conceptpsilocybin, major depressive disorder, clinical trial, self-concept, neuroimaging, fMRI, placebo-controlled, psychedelic therapy, regulatory sciencehttps://mindmedicinelaw.com/briefing/psilocybin-trial-links-self-concept-shifts-to-depression-relief-20260916-42546The Psychedelic Journalen2026-09-17T15:05:59.364463+00:00Psilocybin Trial Links Self-Concept Shifts to Depression Reliefpsilocybin, major depressive disorder, self-concept, clinical trial, neuroimaging, self-referential processing, caudate activation, psychedelic therapy, regulatory pathwayshttps://mindmedicinelaw.com/briefing/improving-psychedelic-clinical-trials-methodology-challenges-and-next-steps-20260916-42463The Psychedelic Journalen2026-09-16T22:07:22.935633+00:00Improving Psychedelic Clinical Trials: Methodology Challenges and Next Stepspsychedelic clinical trials, blinding in trials, expectancy effects, trial reproducibility, FDA guidance, regulatory standards, methodological rigor, psychedelic research, clinical trial design, public health policyhttps://mindmedicinelaw.com/briefing/fda-poised-to-approve-psychedelic-therapy-for-trd-implications-and-next-steps-20260916-42462The Psychedelic Journalen2026-09-16T22:05:27.144886+00:00FDA Poised to Approve Psychedelic Therapy for TRD: Implications and Next Stepsfda approval, psilocybin therapy, treatment-resistant depression, compass pathways, clinical trials, policy implications, insurance coverage, psychedelic medicine, risk evaluation, mental health innovationhttps://mindmedicinelaw.com/briefing/fda-revisits-psychedelic-regulation-implications-for-us-policy-20260916-42304The Psychedelic Journalen2026-09-16T15:05:41.303987+00:00FDA Revisits Psychedelic Regulation: Implications for US Policyfda psychedelic regulation, psychedelic clinical trials, us drug policy, mdma approval process, psilocybin research, controlled substances act, real-world evidence, clinical trial design, patient access, regulatory riskhttps://mindmedicinelaw.com/briefing/fda-psychedelics-hearing-regulatory-pathways-and-policy-signals-2026-20260916-42306The Psychedelic Journalen2026-09-16T15:05:17.605504+00:00FDA Psychedelics Hearing: Regulatory Pathways and Policy Signals (2026)fda psychedelics hearing, psychedelic therapy regulation, clinical trial design, controlled substances act, risk evaluation and mitigation strategies, drug approval pathways, public health policy, market access, real-world evidence, post-approval controlshttps://mindmedicinelaw.com/briefing/fda-public-hearing-on-psychedelics-u-s-policy-at-a-crossroads-20260916-42307The Psychedelic Journalen2026-09-16T15:04:51.155495+00:00FDA Public Hearing on Psychedelics: U.S. Policy at a Crossroadsfda public hearing, psychedelic policy, trump administration, drug rescheduling, clinical research access, industry investment, regulatory risk, insurance reimbursement, us drug law, controlled substances acthttps://mindmedicinelaw.com/briefing/fda-faces-scrutiny-after-death-and-misconduct-in-psychedelic-care-20260916-42305The Psychedelic Journalen2026-09-16T15:04:28.149171+00:00FDA Faces Scrutiny After Death and Misconduct in Psychedelic Carefda, psychedelic-assisted therapy, patient safety, provider misconduct, clinical trial risk, regulatory policy, mdma, psilocybin, adverse events, risk managementhttps://mindmedicinelaw.com/briefing/colorado-psychedelic-decriminalization-policy-limits-and-next-steps-20260915-42779The Psychedelic Journalen2026-09-17T22:04:46.054944+00:00Colorado Psychedelic Decriminalization: Policy, Limits, and Next Stepscolorado psychedelics policy, decriminalization, psilocybin law, state drug reform, research barriers, federal-state conflict, public health risks, therapeutic facilitation, law enforcement, regulatory uncertaintyhttps://mindmedicinelaw.com/briefing/blood-neurofilament-light-chain-as-a-marker-in-substance-using-populations-20260915-42529The Psychedelic Journalen2026-09-17T15:09:40.984117+00:00Blood Neurofilament Light Chain as a Marker in Substance-Using Populationsneurofilament light chain, nfl biomarker, substance use neurotoxicity, psychoactive substances, meta-analysis, clinical trials, public health policy, alcohol neurotoxicity, biomarker specificity, sex differences in neurotoxicityhttps://mindmedicinelaw.com/briefing/mri-study-reveals-brain-circuit-differences-in-gambling-disorder-20260915-42515The Psychedelic Journalen2026-09-17T15:09:23.116135+00:00MRI Study Reveals Brain Circuit Differences in Gambling Disordergambling disorder, mri, addiction neuroscience, prefrontal cortex, limbic system, striatal circuits, psychedelic therapy, functional connectivity, grey matter volume, clinical trialshttps://mindmedicinelaw.com/briefing/trump-s-public-reference-to-psychedelic-therapies-u-s-policy-implications-20260915-42622The Psychedelic Journalen2026-09-17T15:07:53.825173+00:00Trump’s Public Reference to Psychedelic Therapies: U.S. Policy Implicationspsychedelic policy, trump remarks, us federal law, fda breakthrough therapy, clinical trials, public opinion, state-level reform, mdma, psilocybin, regulatory riskhttps://mindmedicinelaw.com/briefing/music-as-a-contextual-variable-in-psychedelic-therapy-trials-20260915-42351The Psychedelic Journalen2026-09-16T22:07:45.991429+00:00Music as a Contextual Variable in Psychedelic Therapy Trialspsychedelic-assisted psychotherapy, music in therapy, clinical trial design, contextual factors, complex interventions, regulatory standards, trial reproducibility, adverse events, functional standardizationhttps://mindmedicinelaw.com/briefing/neurocognitive-model-psychedelics-and-hippocampal-reset-in-anxiety-relief-20260915-42350The Psychedelic Journalen2026-09-16T22:06:42.669265+00:00Neurocognitive Model: Psychedelics and Hippocampal Reset in Anxiety Reliefpsychedelics, anxiety disorders, hippocampal reset, neurocognitive model, psilocybin, clinical trial design, biomarkers, cortical plasticity, regulatory policyhttps://mindmedicinelaw.com/briefing/lived-experience-as-evidence-in-psychedelic-public-health-policy-20260915-42352The Psychedelic Journalen2026-09-16T22:06:26.065111+00:00Lived Experience as Evidence in Psychedelic Public Health Policylived experience, psychedelic public health, clinical trials, policy development, aftercare, systems-relevant evidence, regulatory oversight, patient safety, program evaluationhttps://mindmedicinelaw.com/briefing/psilocybin-ayahuasca-for-trd-evidence-ethics-and-research-gaps-20260915-42353The Psychedelic Journalen2026-09-16T22:06:05.582463+00:00Psilocybin & Ayahuasca for TRD: Evidence, Ethics, and Research Gapspsilocybin, ayahuasca, treatment-resistant depression, clinical trial design, ethical challenges, blinding, informed consent, psychedelic-assisted therapy, regulatory science, methodological limitationshttps://mindmedicinelaw.com/briefing/prenatal-dexamethasone-and-neurogenesis-epigenetic-risks-in-psychiatric-health-20260914-42390The Psychedelic Journalen2026-09-16T22:08:30.483853+00:00Prenatal Dexamethasone and Neurogenesis: Epigenetic Risks in Psychiatric Healthprenatal dexamethasone, hippocampal neurogenesis, epigenetic regulation, psychiatric risk, glucocorticoid exposure, PI3K-Akt-mTOR pathway, psychedelic therapy, depression-like behaviors, neurodevelopment, public health policyhttps://mindmedicinelaw.com/briefing/pharmacogenetics-and-psychotropic-response-implications-for-psychedelic-psychiat-20260914-42399The Psychedelic Journalen2026-09-16T22:08:07.882523+00:00Pharmacogenetics and Psychotropic Response: Implications for Psychedelic Psychiatrypharmacogenetics, cyp2d6, cyp2c19, psychedelic therapy, personalized medicine, clinical trial design, phenoconversion, adverse events, precision psychiatryhttps://mindmedicinelaw.com/briefing/5-ht2a-receptor-mechanisms-and-policy-implications-in-psychedelic-research-20260914-42354The Psychedelic Journalen2026-09-16T22:07:02.123784+00:005-HT2A Receptor: Mechanisms and Policy Implications in Psychedelic Research5-ht2a receptor, psychedelics, mechanism of action, neuroplasticity, clinical trials, mental disorders, policy implications, biomarkers, regulatory sciencehttps://mindmedicinelaw.com/briefing/structured-at-home-ketamine-protocol-clinical-and-policy-implications-20260911-42395The Psychedelic Journalen2026-09-16T22:05:45.663309+00:00Structured At-Home Ketamine Protocol: Clinical and Policy Implicationsat-home ketamine, racemic ketamine protocol, psychiatric treatment, decentralized therapy, route-specific dosing, telemedicine, regulatory standards, patient safety, clinical best practiceshttps://mindmedicinelaw.com/briefing/non-response-to-ketamine-in-trd-clinical-correlates-and-implications-20260910-42568The Psychedelic Journalen2026-09-17T15:10:03.385466+00:00Non-Response to Ketamine in TRD: Clinical Correlates and Implicationsketamine non-responders, treatment-resistant depression, life engagement, clinical trial design, psychedelic-assisted therapy, patient selection, FDA guidance, biomarkers, anhedonia, psychiatric comorbidity